HSCA Comments on FDA Bulk Substance Guidance
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Food and Drug Administration (FDA) draft guidance on the use of bulk substances under Section 503B of the Federal Food, Drug, and Cosmetic Act. HSCA represents the nation’s leading healthcare group purchasing organizations (GPOs), the sourcing and purchasing partners to virtually all of America’s 7,000+ hospitals.
Related Posts
Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace
September 21, 2018
On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the...
HSCA Announces Healthcare Cybersecurity Key Considerations
April 17, 2018
The Healthcare Supply Chain Association (HSCA) today announced the release of key...
HSCA Comments on FDA Bulk Substance Guidance
May 25, 2018
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
HSCA Joins Leading Healthcare Organizations in Supporting the CREATES Act (S.974)
June 7, 2018
We, the undersigned, commend you for your leadership and commitment to reducing...